Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Petrylak, Daniel P.; Tangen, Catherine M.; Hussain, Maha; Lara, Primo N.; Jones, Jeffrey A.; Taplin, Mary Ellen; Burch, Patrick A.; Berry, Donna L.; Moinpour, Carol M.; Kohli, Manish; Benson, Mitchell C.; Small, Eric J.; Raghavan, Derek; Crawford, E. David

doi:10.1056/nejmoa041318

Cited by 3,338 publications

(2,407 citation statements)

References 19 publications

Supporting

Mentioning

2,246

Contrasting

Unclassified

Order By: Relevance

“…3 Unfortunately, in virtually all patients, the disease inevitably advances to the androgen-independent stage within a median of 18-24 months after castration. 4 Two randomized phase III studies, SWOG 99-16 4 and TAX 327, 5 demonstrated that docetaxel-based chemotherapy confers a significant survival benefit of 20%-24% in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with a mitoxantrone regimen. 6 Nevertheless, many patients failed to respond to docetaxel chemotherapy and experienced considerable toxicity.…”

Section: Introductionmentioning

confidence: 99%

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

Qu¹,

Dai²,

Kong³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

This study aims to evaluate the potential value of patient characteristics in predicting overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel-based thermotherapy. A total of 115 patients with mCRPC undergoing a docetaxel q3w regimen were enrolled in this study. A survival analysis was performed using the Kaplan-Meier method. Cox proportional hazards models were used to evaluate the prognostic value of all covariates for OS. OS was also analysed after stratifying patients according to the results of multivariate analysis. The median OS for the entire cohort was 17.0 months. The multivariate analysis showed that the prostate-specific antigen doubling time (PSADT), baseline haemoglobin (Hb) concentration, alkaline phosphatase (ALP) concentration, cycles of chemotherapy and time to castration resistance were independent prognostic factors of OS. According to the presence of PSADT ,46.3 days and baseline ALP o110 IU l 21 , all patients were divided into three risk groups: low-risk group (no risk factors), intermediate-risk group (one risk factor) and high-risk group (two risk factors). Median OSs for patients in low-, intermediate-and high-risk groups were 28.0 months (95% CI: 23.8-32.2), 21.0 months (95% CI: 18.9-23.1) and 11.0 months (95% CI: 7.6-14.4), respectively (P,0.001). In conclusion, PSADT, baseline Hb concentration, ALP concentration, cycles of chemotherapy and time to castration resistance were independent prognostic factors of OS in Chinese patients with mCRPC treated with docetaxel. PSADT combined with the baseline ALP concentration could be a useful risk stratification parameter for evaluating survival outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

Qu¹,

Dai²,

Kong³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…Androgen withdrawal is an effective therapy for patients with advanced prostate cancer, but progression to hormone independence occurs ultimately in almost all patients after a few months or years (Petrylak et al, 2004). Although numerous non-hormonal agents have been evaluated in patients with hormone-refractory prostate cancer, these agents have limited antitumor activity with modest or no effect on survival (Petrylak et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer

et al. 2006

View full text Add to dashboard Cite

“…Of the seven RCTs included, three used docetaxel compared with mitoxantrone plus prednisone (Petrylak et al, 2004;Tannock et al, 2004;Oudard et al, 2005), three used mitoxantrone plus a corticosteroid compared with a corticosteroid (used as active supportive care) (Tannock et al, 1996;Kantoff et al, 1999;Berry et al, 2002) and one used mitoxantrone plus prednisone compared with mitoxantrone plus prednisone plus clodronate (Ernst et al, 2003). There were no trials comparing docetaxel plus prednisolone/prednisone or mitoxantrone plus a corticosteroid with other Figure 1 Process of study selection.…”

Section: Resultsmentioning

confidence: 99%

“…We found three RCTs comparing mitoxantrone plus prednisone with another chemotherapy regimen: one small RCT compared mitoxantrone plus prednisone with 3-weekly docetaxel plus prednisone plus estramustine and docetaxel twice every 3 weeks plus prednisone plus estramustine in 130 men with mHRPC (Oudard et al, 2005); one RCT compared mitoxantrone plus prednisone with 3-weekly docetaxel plus estramustine in 770 men with mHRPC (Petrylak et al, 2004); and one double-blind RCT compared mitoxantrone plus prednisone plus placebo with mitoxantrone plus prednisone plus clodronate in 227 men with mHRPC and stable levels of analgesic use (Ernst et al, 2003). Overall survival and progression-free survival were statistically significantly improved with docetaxel plus estramustine compared with mitoxantrone plus prednisone, response rate was statistically significantly improved with docetaxel plus prednisone plus estramustine compared with mitoxantrone plus prednisone and PSA decline was statistically significantly improved for both regimens containing docetaxel compared with mitoxantrone plus prednisone.…”

Section: Control (N ¼ 123): Hydrocortisone (As Above)mentioning

confidence: 99%

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer

et al. 2006

View full text Add to dashboard Cite

A systematic review was performed to evaluate the clinical effectiveness of docetaxel in combination with prednisolone (docetaxel is licensed in the UK for use in combination with prednisone or prednisolone for the treatment of patients with metastatic hormonerefractory prostate cancer. Prednisone is not used in the UK, but it is reasonable to use docetaxel plus prednisone data in this review of docetaxel plus prednisolone) for the treatment of metastatic hormone-refractory prostate cancer. A scoping search identified a trial of docetaxel plus prednisone vs mitoxantrone plus prednisone, but did not identify any trials comparing docetaxel plus prednisolone/prednisone with any other treatments. Therefore, we considered additional indirect evidence that would enable a comparison of docetaxel plus prednisolone/prednisone with other chemotherapy regimens and active supportive care. Systematic searching (upto April 2005) identified seven randomised controlled trials. One large well-conducted trial assessed docetaxel plus prednisone vs mitoxantrone plus prednisone; this showed statistically significant improvements with 3-weekly docetaxel in terms of overall survival, quality of life, pain response and PSA decline. Two other chemotherapy regimens that included docetaxel with estramustine also showed improved outcomes in comparison with mitoxantrone plus prednisone. Three trials that compared mitoxantrone plus corticosteroids with corticosteroids alone were identified and their results for overall survival combined, which showed very little difference between the two groups. The addition of clodronate to mitoxantrone plus prednisone showed no significant differences in comparison with mitoxantrone plus prednisone alone. The evidence suggests that chemotherapy regimens containing 3-weekly docetaxel are superior to mitoxantrone or corticosteroids alone.

show abstract

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Abstract: The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.

Cited by 3,338 publications

References 19 publications

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer

Contact Info

Product

Resources

About